Department of Health Policy and Management, School of Medicine, Keio University.
Research Department, Institute for Health Economics and Policy, Association for Health Economics Research and Social Insurance and Welfare.
Tohoku J Exp Med. 2020 Oct;252(2):143-152. doi: 10.1620/tjem.252.143.
Secondary prevention with medications is essential for the better prognosis of patients who have experienced cardiovascular events. We aimed to evaluate the use of guideline-based medications for secondary prevention in older adults in the community settings after discharge following percutaneous coronary intervention (PCI). A retrospective cohort study was conducted using anonymized claims data of older beneficiaries in a suburban city of Japan between April 2012 and March 2015. The prescriptions of antiplatelets, statins, angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARB), and β-blockers were evaluated for 3 months before and after the month in which the participants underwent PCI. Multivariable logistic regression analysis was conducted to evaluate the associations of age ("pre-old" group [63-72 years] vs. "old" group [≥ 73 years]) and sex with the prescriptions, adjusting for whether a participant was followed-up by the PCI-performing hospital. Of 815 participants, 59.6% constituted the old group and 70.9% were men. The prescription rates for antiplatelets, statins, ACEi/ARB, and β-blockers after discharge were 94.6%, 65.0%, 59.3%, and 32.9%, respectively. The adjusted analysis indicated that statins were less likely to be prescribed for the old group (adjusted odds ratio [aOR], 0.70; 95% confidence interval [CI], 0.51-0.95; p = 0.023) and for men (aOR, 0.64; 95% CI, 0.45-0.89; p = 0.008). β-blockers were more likely to be prescribed for men (aOR, 1.66; 95% CI, 1.17-2.33; p = 0.004). Our results suggest the potential for improvements in secondary prevention by increasing the prescription rates of guideline-based medications in this population.
二级预防药物治疗对于经历过心血管事件的患者预后改善至关重要。我们旨在评估在日本郊区社区环境中,经皮冠状动脉介入治疗(PCI)出院后的老年患者二级预防中指南指导药物的使用情况。本研究采用回顾性队列研究,使用日本郊区城市 2012 年 4 月至 2015 年 3 月间老年受益人的匿名理赔数据。评估了参与者接受 PCI 前后 3 个月内抗血小板、他汀类药物、血管紧张素转换酶抑制剂(ACEi)/血管紧张素 II 受体阻滞剂(ARB)和β受体阻滞剂的处方情况。采用多变量逻辑回归分析评估年龄(“老年前”组[63-72 岁]与“老年”组[≥73 岁])和性别与处方的相关性,调整了参与者是否由行 PCI 的医院进行随访。815 名参与者中,59.6%为老年组,70.9%为男性。出院后抗血小板、他汀类药物、ACEi/ARB 和β受体阻滞剂的处方率分别为 94.6%、65.0%、59.3%和 32.9%。调整分析表明,与老年组(调整优势比[aOR],0.70;95%置信区间[CI],0.51-0.95;p=0.023)和男性(aOR,0.64;95%CI,0.45-0.89;p=0.008)相比,他汀类药物的处方率较低。β受体阻滞剂更可能为男性开具处方(aOR,1.66;95%CI,1.17-2.33;p=0.004)。我们的研究结果表明,通过提高该人群指南指导药物的处方率,可能会改善二级预防。